MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 91 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,513 | +4.9% | 5,400 | 0.0% | 0.40% | -3.8% |
| Q1 2024 | $1,442 | +24.6% | 5,400 | +8.0% | 0.42% | +17.6% |
| Q4 2023 | $1,157 | +58.5% | 5,000 | 0.0% | 0.36% | +40.9% |
| Q3 2023 | $730 | -51.4% | 5,000 | -23.1% | 0.25% | -47.5% |
| Q2 2023 | $1,501 | -4.7% | 6,500 | 0.0% | 0.48% | -13.6% |
| Q1 2023 | $1,575 | -99.6% | 6,500 | 0.0% | 0.56% | +229.4% |
| Q3 2022 | $422,000 | -9.2% | 6,500 | 0.0% | 0.17% | -5.0% |
| Q2 2022 | $465,000 | -52.6% | 6,500 | -35.0% | 0.18% | -35.6% |
| Q1 2022 | $981,000 | +5.3% | 10,000 | -9.1% | 0.28% | +17.3% |
| Q4 2021 | $932,000 | -6.5% | 11,000 | -12.0% | 0.24% | -15.7% |
| Q3 2021 | $997,000 | -26.9% | 12,500 | -10.7% | 0.28% | -27.0% |
| Q2 2021 | $1,364,000 | +6.0% | 14,000 | +27.3% | 0.38% | -11.5% |
| Q1 2021 | $1,287,000 | -3.5% | 11,000 | -8.3% | 0.44% | -9.4% |
| Q4 2020 | $1,334,000 | -6.4% | 12,000 | 0.0% | 0.48% | -12.2% |
| Q3 2020 | $1,425,000 | +4.9% | 12,000 | 0.0% | 0.55% | -11.6% |
| Q2 2020 | $1,359,000 | +69.7% | 12,000 | 0.0% | 0.62% | +15.1% |
| Q1 2020 | $801,000 | -49.5% | 12,000 | -31.0% | 0.54% | +2.5% |
| Q4 2019 | $1,585,000 | +12.5% | 17,400 | +6.5% | 0.52% | -5.7% |
| Q3 2019 | $1,409,000 | -12.4% | 16,341 | +6.5% | 0.56% | -11.4% |
| Q2 2019 | $1,608,000 | -16.3% | 15,341 | 0.0% | 0.63% | -21.9% |
| Q1 2019 | $1,922,000 | +18.9% | 15,341 | +7.0% | 0.80% | -4.7% |
| Q4 2018 | $1,617,000 | -50.8% | 14,341 | -6.5% | 0.84% | -33.9% |
| Q3 2018 | $3,285,000 | -33.0% | 15,341 | -12.5% | 1.28% | -37.7% |
| Q2 2018 | $4,906,000 | +90.6% | 17,541 | -20.4% | 2.05% | +75.2% |
| Q1 2018 | $2,574,000 | +21.2% | 22,041 | -4.8% | 1.17% | +17.9% |
| Q4 2017 | $2,124,000 | +104.0% | 23,141 | 0.0% | 0.99% | +119.9% |
| Q3 2017 | $1,041,000 | +323.2% | 23,141 | +52.8% | 0.45% | +326.4% |
| Q2 2017 | $246,000 | – | 15,141 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paulson & Co. | 1,850,000 | $518,296,000 | 38.31% |
| Tao Capital Management LP | 130,529 | $36,569,005 | 29.98% |
| University of Wisconsin Foundation | 45,730 | $12,811,717 | 14.42% |
| AlpInvest Partners B.V. | 84,595 | $23,700,135 | 8.50% |
| RTW INVESTMENTS, LP | 1,915,862 | $536,747,898 | 8.31% |
| Propel Bio Management, LLC | 43,032 | $12,055,845 | 7.82% |
| Avoro Capital Advisors LLC | 2,055,555 | $575,884,289 | 7.67% |
| Baker Brothers Advisors | 1,974,590 | $553,201,134 | 7.07% |
| Tri Locum Partners LP | 65,352 | $18,309,016 | 4.63% |
| TCG Crossover Management, LLC | 149,283 | $41,823,125 | 4.36% |